Know Cancer

or
forgot password

Results of Phase III Study to Assess if Zoledronic Acid Have Antumor Activity in Multiple Myeloma


N/A
18 Years
65 Years
Not Enrolling
Both
Multiple Myeloma

Thank you

Trial Information

Results of Phase III Study to Assess if Zoledronic Acid Have Antumor Activity in Multiple Myeloma


Assess if the use of zoledronic acid can improve outcome in patients with multiple myeloma
whose are treated with cytoreductive therapy and stem cell transplant.


Inclusion Criteria:



Diagnosis of multiple myeloma No previous treatment Symptomatic High risk (ISS) or stage
III ( Durie-Salmon) No severe comorbidities -

Exclusion Criteria:

Pregnancy HIV + Refuse treatment

-

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

progression-free disease and overall toxicity in myeloma multiple

Outcome Description:

In patients treated with cytoreductive therapy following by stem cell transplant and that received zoledronic acid by 2 years,they were evaluable for assess antitumor effect of zoledronic acid

Outcome Time Frame:

3 years

Safety Issue:

No

Principal Investigator

Agustin Aviles, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Instituto Mexicano del Seguro Social

Authority:

Mexico:Mexican Institute of Social Security

Study ID:

kitty1

NCT ID:

NCT01234129

Start Date:

June 2002

Completion Date:

December 2009

Related Keywords:

  • Multiple Myeloma
  • multiple myeloma
  • stem cell transplant
  • zoledronic acid
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location